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Abstract Recent studies point to the involvement of angio-
tensin II (Ang II) receptor type 1 (AT-1R) on processes of
metastasing, stimulation of invasiveness and angiogenesis in
tumours. In this study, the correlation between intensity of
AT-1R expression and expression of lymph- and angiogen-
esis markers in invasive ductal breast cancers (IDC) was
examined. Immunohistochemical studies (IHC) were per-
formed on archival material of 102 IDC cases. Only 28
(27.5%) cases manifested low AT-1R expression while 74
(72.5%) cases demonstrated a moderate or pronounced AT-
1R expression. Expression intensity of AT-1R was found to
correlate with expressions of VEGF-A (r00.26; p00.008)
and VEGF-D (r00.24; p00.015). Out of the examined
markers of angiogenesis and lymphangiogenesis only the
pronounced expression of VEGF-C was found to correlate
with patient poor clinical outcome (p00.009). The positive
correlation between AT-1R and VEGF-A and VEGF-D
could point to stimulatory action of Ang II on their expres-
sion what might result in augmented lymph- and angiogenesis
in IDC.
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Introduction
Breast cancer is the most frequent female malignancy all
over the world. In 2008 its incidence was appraised at 1.38
million new cases (23% of all tumours) with increasing
frequency of its manifestation [1, 2].
Angiotensin II (Ang II) represents an important element
of renin-angiotensin system (RAS). It is a multifunctional
octapeptide, formed by excision of two amino acids (histi-
dine and leucine) from carbonyl terminus of its precursor,
angiotensin I. The reaction is executed by angiotensin con-
verting enzyme (ACE), secreted mainly by the endothelium
of pulmonary blood vessels [3]. Ang II acts via two types of
receptors, AT-1R and AT-2R, which are coupled to G pro-
teins [4]. Ang II stimulates the release of aldosteron, vaso-
pressin and nitrogen oxide. It is involved in the development
of oxidative stress, inflammatory processes, maintenance of
an appropriate level of body electrolytes and water, in blood
vessel remodelling, processes of vascular atherogenesis and
it stimulates the contraction of vascular myocytes [5–7].
Expression of AT-1R was demonstrated in cells of several
organs [8]. On the other hand, angiotensin type 2 receptor
(AT-2R), responsible, i.a., for induction of apoptosis, is less
A. Jethon : B. Pula :A. Piotrowska : P. Dziegiel :
M. Podhorska-Okolow (*)




A. Wojnar : P. Dziegiel
Department of Pathomorphology,
Lower Silesian Centre of Oncology,
Wroclaw, Poland
J. Rys




Department of Histology and Embryology,
Poznan University of Medical Sciences,
Poznan, Poland
Pathol. Oncol. Res. (2012) 18:867–873
DOI 10.1007/s12253-012-9516-x
common and expressed mainly in fetal cells. In an adult
healthy organism, it is expressed in cells of vascular endo-
thelium, uterine muscle, ovaries, some cerebral structures
and in selected structures of skin, kidneys, heart [9, 10].
Several earlier studies pointed to a significant function of
Ang II on several aspects of neoplastic disease and com-
pounds suppressing action of Ang II were suggested to have
an anti-neoplastic significance [11]. Overexpression of AT-
1R was observed in many types of tumours including
tumours of pancreas, kidneys and lungs [12–14].
In mammary gland, presence of both receptor types was
demonstrated [8]. AT-1R is located in epithelial cells of
alveoli and lactiferous ducts, both in the healthy tissue and
in benign tumours (15). Increased levels of AT-1R mRNA
were observed in hyperplastic lesions, in ductal breast can-
cer in situ (DCIS) and in IDC [16]. AT-1R activation by Ang
II resulted in proliferation of breast cancer cells [7, 17]. In
cases of metastazing IDC only a weak cytoplasmic expres-
sion of AT-1R was demonstrated [6]. The till now performed
studies showed also that breast cancer cells may acquire
metastazing ability i.a. due to changes in activity and acces-
sibility of Ang II in the pathway linked to AT-1R [18, 19]. It
was also shown that blockade of AT-1R decreased invasive-
ness of tumour cells [20]. No such effect was shown in the
case of AT-2R. The results of the studies mentioned above
point to a potential of applying AT-1R blockers in anti-
neoplastic therapy [19].
Ang II is also engaged in the process of angiogenesis, of
key importance from the point of view of neoplastic progres-
sion [21, 22]. In numerous studies stimulatory effect of Ang II
on the formation of new blood vessels was shown [23].
Moreover, blockade of ACE andAT-1R significantly inhibited
development of many tumour types (breast cancer, non-small
cell pulmonary cancer, gastric cancer) and decreased the den-
sity of blood vessels as well as their metastatic potential [12,
24]. In the case of tumour lymphangiogenesis no data are
currently available on the involvement of Ang II.
In this study, we undertook an attempt to define the
significance of AT-1R expression, with particular attention
paid to its correlation with selected markers of angiogenesis
(CD31, VEGF-A) and lymphangiogenesis (D2-40, Lyve-1,
VEGF-C and VEGF-D) in IDC.
Material and Methods
Patients
The studies were conducted on archival paraffin blocks of
IDC subjected to radical surgery in 1999–2002 in the Lower
Silesia Centre of Oncology in Wroclaw. Clinical and path-
ological data were obtained from hospital archives. A group
of 102 patients, aged between 30 and 83 years (mean of
56 years) was retrospectively analyzed. Duration of obser-
vation ranged between 1 and 125 months (mean of
61 months). The clinical and pathological data are summa-
rized in Table 1.
Immunohistochemistry (IHC)
Immunohistochemical reactions were performed on paraffin
sections using DAKO Autostainer Link48 (Dako, Glostrup,
Denmark) in case of the following antibodies in respective
concentrations: mouse anti-AT-1R (24.7 μg/ml; Abcam,
Cambridge, UK), mouse anti-CD31 (0.69 μg/ml; Leica
Microsystems, Wetzlar, Germany), mouse anti-D2-40
(RTU; Dako), mouse anti-VEGF-A (1 μg/ml; Dako) and
mouse anti-Ki-67 (clone MIB-1, 0.8 μg/ml; Dako). In order
Table 1 Clinical and
pathological data of 102
studied cases of IDC
Parameter Number of cases %
Patient’s age
≤ 50 35 34.3





≤ 2 cm 64 62.7























≤ 25% 76 74.5
> 25% 26 25.5
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to deparaffinize, rehydrate and unmask the antigens the
sections were boiled in Target Retrieval Solution buffer
(pH 9; Dako) using Pre-Treament Link Platform (Dako)
and, subsequently, cooled in a rinsing buffer (TBS). En-
Vision™ FLEX (Dako) was used to visualize the antigens.
Only in the case of VEGF-A IHC reaction, incubation
with primary antibodies was extended from 20 min at
RT to 18 hours at the temperature of 4°C and reaction
was amplified using the EnVision™ FLEX + Mouse
LINKER system (Dako).
Reactions with ER-specific antibodies (detecting estro-
gen receptors), PR-specific antibodies (detecting proges-
teron receptors) and with HER-2-specific antibodies were
conducted according to the earlier described procedure
[25]. The sections were deparaffinized and rehydrated in
Antigen Retrieval Solution (pH 6; Dako). Activity of
endogenous peroxidase was blocked by 5 min incubation
in 3% H2O2. Subsequently, primary antibodies to ER
(clone 1D5, 1:100) or PR (clone PgR 636, 1:100) and
incubated for 1 h at RT. The subsequent reaction stages
followed manufacturer’s instructions for the LSAB +
System-HRP visualization system (Dako). 3,3′-diamino-
benzidine (DAB) was used as a chromogen. In order to
visualize expression of HER2, the HercepTest™ kit
(Dako) was used, according to the procedure recommended
by the producer.
In order to examine the expression of VEGF-C, VEGF-D
and Lyve-1, mouse antibodies anti-VEGF-C (2 μg/ml), anti-
VEGF-D (2 μg/ml) and anti-Lyve-1 (1 μg/ml) were used
(ReliaTech GmbH, Braunschweig, Germany). The sections
were deparaffinized in xylene, rehydrated and boiled in a
citrate buffer, pH 6 (for VEGF-C, Lyve-1) or pH 9 (for
VEGF-D). Subsequently, activity of endogenous peroxidase
was blocked by 5 min incubation in 3% H2O2. The sections
were incubated with primary antibody overnight at the tem-
perature of 4°C (VEGF-C, VEGF-D) or for 30 min at room
temperature (Lyve-1). Then the antigens were visualized
using the EnVision™ Detection Systems Peroxidase/DAB,
Rabbit/Mouse (Dako).
All slides were counterstained with Mayer’s hematoxylin
(Dako). Subsequently, the preparations were mounted in
SUB-X Mounting Medium (Dako).
Evaluation of IHC Reactions
In all cases hematoxylin-eosin (H + E) staining of the
preparations was performed in order to determine grade of
tumour (G) and to evaluate the extent of necrosis in the
tumours.
The intensity of IHC reactions for AT-1R, VEGF-A,
VEGF-C and VEGF-D was estimated using the semi-
quantitative immunoreactive (IRS) scale of Remmele and
Stegner [26]. Determination of Ki-67 antigen expression
employed a five grade scale, reflecting percentage of tumour
cells manifesting a nuclear reaction: 0% - 0, 1–10% - 1, 11–
25% - 2, 26–50% - 3, 51–100% - 4. For quantification of
blood vessel and lymphatic vessel densities in the tumour
and in the peritumoural area (CD31+, Lyve-1+ and D2-40+)
Chalkley point array (Pyser Sgi., Edenbridge, UK) was
used. Under magnification of 200x, the vessels were
scored in three intratumoural and peritumoural areas of
potentially the highest density (hot spots). All the preparations
were examined using OLYMPUS BX-41 light microscope
(Olympus, Tokyo, Japan).
Statistical Analysis
The results were subjected to statistical analysis using Prism
5.0 (GraphPad, CA, USA). Relationships between expres-
sion of studied markers and clinicopathological factors were
examined using the Spearman rank correlation test, the
Kruskal-Wallis test and the exact Fisher’s test. Kaplan-
Meier’s survival curves for the patients survival were ana-
lysed using the test of Mantel Cox. The differences were
regarded significant at p<0.05.
Results
Expression of AT-1R in Ductal Breast Cancer
and its Correlation with Clinical and Pathological Data
In most cases (101; 99.1%) cytoplasmic expression of AT-
1R was noted. Among them, 28 (27.5%) cases demonstrated
low expression of AT-1R (IRS 0–4) (Fig. 1a), while 74
(72.5%) cases manifested moderate or high expression of
AT-1R (IRS 6–12) (Fig 1b). Expression of AT-1R was
detected also in the cells of tumour stroma. No significant
differences were disclosed in AT-1R expression, which
would be related to degree of the tumour malignancy. Ex-
pression of AT-1R failed to correlate with patients’ age,
tumour size or presence of metastases to lymph nodes, with
expressions of ER, PR or expression of HER2 receptor
(Table 2). Expression of AT-1R did not correlate with ex-
pression of Ki-67 proliferation antigen (Sperman’s rank
correlation test, p00.85).
Correlation Between AT-1R Expression and Markers
of Angiogenesis and Lymphangiogenesis
All the studied vascular endothelial growth factors (VEGF-A,
VEGF-C and VEGF-D) manifested a cytoplasmic reaction in
tumour cells. A pronounced expression of VEGF-Awas noted
in 52 (51%), of VEGF-C in 56 (54.9%), and of VEGF-D in 48
(47.1%) studied cases. A moderately positive correlation was
documented between expression of AT-1R on one hand and
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expression of VEGF-A (r00.26, p00.008) and VEGF-D ex-
pression (r00.24, p00.015) on the other (Table 3).
No correlation was disclosed between the density of CD31+
blood vessels expressed intra- and peritumorally and the inten-
sity of AT-1R expression. Also no relationship could be dis-
closed between the intensity of AT-1R expression and the
density of Lyve-1+ and D2-40+ lymphatic vessels (Table 4).
Effect of AT-1R Expression on Patients’ Outcome
No significant differences were noted in patients survival
regarding the intensity of AT-1R expression (Fig. 2a). The
variables which significantly affected duration of patients’
survival were primary tumour size (pT) (p00.028), presence
of lymph nodes metastases (pN) (p00.0005) and high in-
tensity of VEGF-C expression (p00.009) (Figs. 2b–d,
respectively).
Discussion
Results of earlier studies showed that the function of RAS
system is not restricted exclusively to processes controlling
body ions turnover but it may play a significant role in
processes of proliferation, apoptosis and cell differentiation
and significantly affect angiogenesis in neoplastic tumours
[27]. Apart from function of the systemic RAS system,
activities of a local RAS system have been demonstrated
in several types of normal and neoplastic tissues, including
tissues and cancers of the breast [8, 15]. Moreover, in
malignant lesions an increased AT-1R mRNA expression
was demonstrated, as compared to healthy cells of mamma-
ry gland [4]. However, a decreased expression of AT-1R
protein was detected by some authors in mammary cancers
[28]. In turn, studies of Puddefoot et al. demonstrated in-
creased metastatic potential of breast cancer cells dependent
on integrin expression changes due to Ang II stimulation
[18]. Ang II was also shown to promote cell proliferation by
binding to AT-1R, by the activation of the phosphokinase C
(PKC), what resulted in calcium ions mobilization [7, 28].
In addition, a stimulatory effect of Ang II on expression of
VEGF-A was demonstrated exclusively in triple negative
Table 2 Correlation between AT-1R expression and selected clinical
and pathological parameters
Variable Number of cases (%) AT-1R—number (%) p
IRS 0-4 IRS 6-12
Age
≤50 35 (34.3) 14 (40.0) 21 (60.0) 0.0601
>50 67 (65.7) 14 (20.9) 53 (79.1)
Menopause
Pre 38 (31.3) 13 (34.2) 25 (63.8) 0.2588
Post 64 (68.7) 15 (23.5) 49 (76.5)
pT
≤ 2 cm 64 (62.7) 19 (29.7) 45 (70.3) 0.6473
> 2 cm 38 (37.3) 9 (23.6) 29 (76.4)
pN
pN0 52 (51.0) 14 (26.9) 38 (73.1) 1.0000
pN1-3 50 (49.0) 14 (28.0) 36 (72.0)
ER
Positive 81 (79.4) 22 (27.1) 59 (72.9) 1.0000
Negative 21 (20.6) 6 (28.6) 15 (71.4)
PR
Positive 68 (66.7) 20 (29.4) 48 (70.6) 0.6404
Negative 34 (33.3) 8 (23.5) 26 (76.5)
HER2
Positive 15 (14.7) 3 (20.0) 12 (80.0) 0.7547
Negative 87 (85.3) 62 (71.2) 15 (13.8)
Table 3 Correlation between AT-1R expression and expression of






Fig. 1 IDC cases with low (a) or high (b) expression of AT-1R.
Magnification 200x
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breast cancer (with no expression of ER, PR, HER2), but
not on other breast cancer cell lines [19].
Results of our IHC investigations have documented a
positive correlation of AT-1R expression intensity with the
intensity of VEGF-A expression, corroborating earlier results
obtained on other tumours with use of AT-1R blockers, which
inhibited growth of tumour cells [20, 27, 29–33]. We have
demonstrated also a positive correlation between AT-1R
expression and intensity of VEGF-D expression. Earlier
results related to the role of VEGF-D expression in neoplastic
progression frequently yielded equivocal results [34–36].
According to Gu et al., increased expression of VEGF-D in
breast cancer cells correlated with the development of metas-
tases to lymph nodes and patients shorter survival [34]. On the
other hand, studies of Gisterek et al., Mohammad et al. and
Mylon et al. did not demonstrate any unfavourable effect of
VEGF-D expression on patients’ survival [35, 37, 38]. More-
over, the results of studies investigating the relationship be-
tween expression of VEGF-D and the density of lymphatic
vessels were contradictory [34–36]. In our study, similarly to
the results of Mohammad et al. and Gisterek et al., an increase
in VEGF-D expression has not correlated with patients shorter
survival, whereas a more pronounced expression of VEGF-C
was associated with patients poor clinical outcome, confirm-
ing earlier reports [35, 38].
No relationship has been documented between the intensity
of AT-1R expression and densities of blood and lymphatic
vessels (both within the tumour and in the peritumoral area),
although a positive correlation has been noted between AT-1R
expression and intensities of VEGF-A and VEGF-D expres-
sion. Earlier studies of Herr et al. performed on clinical mate-
rial of breast cancer and on two cellular models of the tumour
suggested that Ang II might stimulate production of proangio-
genic factors only in cases of triple negative breast cancers
[19]. Many controversies have been noted on positive effects
of intraepithelial growth factors on processes of angiogenesis
and lymphangiogenesis, since the studies were performed on
Table 4 Correlation between AT-1R expression and selected markers
of vascular density (CD31, Lyve-1, D2-40)
Marker Number of cases (%) AT-1R—Number (%) p
IRS 0-4 IRS 6-12
CD31 Intra
≤ 4 24 (23.5) 8 (33.3) 16 (66.7) 0.4475
> 4 78 (76.5) 20 (25.6) 58 (74.4)
CD31 Peri
≤ 6 44 (43.1) 14 (31.8) 30 (68.2) 0.5021
> 6 58 (56.9) 14 (24.1) 44 (75.9)
Lyve-1 Intra
≤ 1 96 (94.1) 27 (28.1) 69 (71.9) 0.3773
> 1 6 (5.9) 1 (16.7) 5 (83.3)
Lyve-1 Peri
≤ 4 77 (75.5) 19 (24.7) 58 (75.3) 0.3068
> 4 25 (24.5) 19 (76.0) 6 (14.0)
D2-40 Intra
≤ 2 51 (50.0) 11 (21.6) 40 (78.4) 0.2676
> 2 51 (50.0) 17 (33.3) 34 (66.7)
D2-40 Peri
≤ 4 52 (51.0) 12 (23.1) 40 (76.9) 0.3733
> 4 50 (49.0) 16 (32.0) 34 (68.0)
Intra—intratumoural vessels, Peri—peritumoural vessels
Fig. 2 Kaplan-Meier’s diagram
of survival for 102 patients, as
related to intensity of AT-1R
expression (a), primary tumour
size (b), presence lymph node
metastases (c) and intensity of
VEGF-C expression (d)
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animals and frequently could not be reproduced on the clinical
material of ductal breast cancer [39]. Moreover, angiogenic
processes are influenced not only by tumour cells but also by
tumour-associated fibroblasts and macrophages [40–42].
Our studies have demonstrated no relationship between
intensity of AT-1R expression and some clinicopathological
parameters, i.e. grade of malignancy, primary tumour size,
presence of lymph node metastases, menopausal status or
expression of ER, PR and HER2 receptors. In addition,
statistical analysis has documented no effects of AT-1R
expression intensity on survival of the patients.
Although our results have documented no relationships
between AT-1R expression intensity and the listed clinico-
pathological parameters, in our opinion studies on the role
of RAS in development of breast cancer should be contin-
ued, taking into account all proteins composing the system.
Aside from our results, such a conclusion stems also from
recent reports suggesting significant effects of an imbalance
between activities of angiotensin-converting enzymes (ACE
and ACE2) in the development of breast cancer [43]. This
hypothesis was confirmed by studies demonstrating a
marked increase in incidence of breast cancer in women
carrying D/D allele of the ACE gene, which is linked to
higher levels of the circulating ACE isoform in blood of
these patients [44, 45]. In addition, our results have con-
firmed effect of AT-1R on expression of VEGF-A. We have
detected also a positive correlation between intensities of
AT-1R expression and VEGF-D expression in IDC, which
may have significance in better understanding the processes
of lymphangiogenesis in IDC.
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